FindTrial
Sign In

The Mechanism of PD1/PDL1 Inhibitors mediating Cardiovascular Damage

The Mechanism of PD1/PDL1 Inhibitors mediating Cardiovascular Damage

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500107049
Enrollment
Unknown
Registered
2025-08-01
Start date
2025-08-02
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tumor heart disease

Interventions

Case Group group:None
Control group:None

Sponsors

The Second Hospital of Lanzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1 Tumor patients diagnosed with solid tumors; 2 The use of PD1/PDL1 monoclonal antibody drugs alone or in combination during treatment; 3 Those who can tolerate the use of PD1/PDL1 monoclonal antibody drugs for three or more cycles; 4 Patients voluntarily participated in this cross-sectional study and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1 Those with a history of myocarditis, arrhythmia, chronic heart failure, or severe heart valve disease; 2 The patient did not agree to participate in this cross-sectional study.

Design outcomes

Primary

MeasureTime frame
ECG;fosl;—

Countries

China

Contacts

Public ContactLuosha Wang

The Second Hospital of Lanzhou University

409169213@qq.com+86 139 1939 0140

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026